乳腺癌多药耐药与HER-2基因表达相关性研究
|
摘要
目的探讨乳腺癌组织中多药耐药指标P-糖蛋白(P170)、胚胎性谷胱甘肽-S-转移酶-π(GST-π)和DNA拓扑异构酶Ⅱ(TOPOⅡ)与人表皮生长因子受体2(HER-2)基因表达的相关性及临床意义。
方法乳腺癌组织48例。采用荧光原位杂交法(Fluorescence in situ hybridization, FISH)检测HER-2基因的表达；采用免疫组化法(Immunohistochemistry, IHC)检测已知HER-2基因表达情况的乳腺癌病例标本中P170、GST-π和TOPOⅡ的表达情况；分析三者与临床病理因素(年龄、原发肿瘤大小、有无淋巴结转移)的关系及与HER-2基因的相关性。应用SPSS13.0统计学软件行X~2检验及Spearman相关性检验,显著性检验水准α=0.05(双侧)。
结果48例乳腺癌中HER-2基因表达者阳性为22例(45.8%)。P170、GST-π、TOPOⅡ阳性表达率分别为43.8%(21/48)、39.6%(19/48)、56.3%(27/48)。P170、GST-π、TOPOⅡ表达与年龄、原发肿瘤大小、淋巴结转移无关(P>0.05)。P170、GST-π、TOPO表达率在HER-2阳性病例中明显高于HER-2阴性的病例(P<0.05)。P170、GST-π、TOPO表达与HER-2基因表达存在相关性(P<0.05)。
结论P170、GST-π、TOPOⅡ表达与HER-2呈正相关,均可作为临床上检测及指导治疗的重要指标。
Objective To investigate the correlation between the expression of P170, GST-π, TOTOII and the expression of HER-2in human breast cancer.
Methods The expression of HER-2was detected by fluorescence in situ hybridization. The expression of P170, GST-π, TOTOII were tested in48cases breast cancer by immunohistochemical method, and their correlations with clinicopathological feathers and the expression of HER-2were analyzed.
Results The positive rate of P170, GST-π, TOTOII were43.8%,39.6%,56.3%respectively. The expression of P170, GST-π, TOTOII positively correlated with the expression of HER-2(P<0.05). The levels of P170, GST-π, TOTOII expression were not associated with age, primary tumor and lymph node metastasis(P>0.05).
Conclusion There was great possibility of chemotherapy drug resistance in breast cancer with expression of HER-2. Expressions of P170, GST-π, TOTOII and HER-2have an instructive significance for chemotherapy.
方法乳腺癌组织48例。采用荧光原位杂交法(Fluorescence in situ hybridization, FISH)检测HER-2基因的表达；采用免疫组化法(Immunohistochemistry, IHC)检测已知HER-2基因表达情况的乳腺癌病例标本中P170、GST-π和TOPOⅡ的表达情况；分析三者与临床病理因素(年龄、原发肿瘤大小、有无淋巴结转移)的关系及与HER-2基因的相关性。应用SPSS13.0统计学软件行X~2检验及Spearman相关性检验,显著性检验水准α=0.05(双侧)。
结果48例乳腺癌中HER-2基因表达者阳性为22例(45.8%)。P170、GST-π、TOPOⅡ阳性表达率分别为43.8%(21/48)、39.6%(19/48)、56.3%(27/48)。P170、GST-π、TOPOⅡ表达与年龄、原发肿瘤大小、淋巴结转移无关(P>0.05)。P170、GST-π、TOPO表达率在HER-2阳性病例中明显高于HER-2阴性的病例(P<0.05)。P170、GST-π、TOPO表达与HER-2基因表达存在相关性(P<0.05)。
结论P170、GST-π、TOPOⅡ表达与HER-2呈正相关,均可作为临床上检测及指导治疗的重要指标。
Objective To investigate the correlation between the expression of P170, GST-π, TOTOII and the expression of HER-2in human breast cancer.
Methods The expression of HER-2was detected by fluorescence in situ hybridization. The expression of P170, GST-π, TOTOII were tested in48cases breast cancer by immunohistochemical method, and their correlations with clinicopathological feathers and the expression of HER-2were analyzed.
Results The positive rate of P170, GST-π, TOTOII were43.8%,39.6%,56.3%respectively. The expression of P170, GST-π, TOTOII positively correlated with the expression of HER-2(P<0.05). The levels of P170, GST-π, TOTOII expression were not associated with age, primary tumor and lymph node metastasis(P>0.05).
Conclusion There was great possibility of chemotherapy drug resistance in breast cancer with expression of HER-2. Expressions of P170, GST-π, TOTOII and HER-2have an instructive significance for chemotherapy.
引文
[1]杨黎,朱霞,冉立.HER-2、PCNA。Bcl-2、Bax在乳腺癌中的表达与预后的关系.癌症.2007,26(7)：765-761.
[2]Press MF, Slamon DJ, Flom KJ, et al. Evaluation of HER-2/neu gene amplification and overexpression:comparison of frequently used assay methods in a molecularly characterized cohort of breast cancer specimens. J Clin Oncol,2002, 20(14):3095-3105.
[3]Ross JS, Gray GS. Targeted therapy for cancer:the HER-2/neu and Herceptin story. Clin Leadersh Manag Rev,2003,17 (6):333-340.
[4]丁渭,郑春艳,贺智敏,等.HER-2介导乳腺癌细胞多药耐药的作用和机制.国际病理科学与临床杂志.2005,25(5)：381-385.
[5]Ambudkar SV, Dey S, Hrycyna CA, et al. Biochemical, cellular and pharmacological aspects of the multidrug transporter. Annu Rev Pharmacol Toxicol,1999,39:361-398.
[6]Trock BJ, Leonessa F, Clarke R. Multidrug resistance in breast cancer:a meta-analysis of MDR1/gp170 expression and its possible functional significance. J Natl Cancer Inst.1997,89(13):917-931.
[7]孙浩,于晓东P-gp、GST-π、C-erbB-2在乳腺癌中的表达及临床意义.中国普外基础与临床杂志.2009,26(1)：56-59.
[8]陈亦欣,陈伟,王秀清,等.乳腺癌组织中MDR1, TOPOⅡ和C-erbB-2的表达及其相互关系.中国现代医学杂志.2003,13(16)：31-34.
[9]Chung HC, Rha SY, Kim JH, et al. P-glycoprotein:the intermediate end point of drug response to induction chemotherapy in locally advanced breast cancer. Breast Cancer Res Treat.1997,42(1)：65-72.
[10]Bellamy CO, Harrison DJ. Evaluation of glutathione-S-transferase Pi in non-invasive ductal carcinoma of breast. Br J Cancer.1994,69(1):183-185.
[11]李杰,许良中,吴炅.三种耐药基因蛋白表达在乳腺癌中的临床意义.癌症.2001,20(8)：866-868.
[12]位嘉,刘芳芳,付丽.拓扑异构酶Ⅱα在乳腺癌中的研究现状.中华病理学杂志.2008,37(2)：132-135.
[13]连婧,李丽,孙瑞芳,等.乳腺癌组织中Ki67、C-erbB-2、VEGF表达的相关性及临床意义.山西医科大学学报,2009,40(2)：125-127.
[14]Rohan TE, Li SQ, Hartwick R, et al. p53 alterations and protein aecmulation in benign breast tissue and breast cancer risk:aeohort study. Cancer Epidemiol Biomarkers Prey,2006,15(7):1316-1323.
[15]Li-Ning-T E, Ronchetti R, Torres-Cabala C, el al. Role of chromogenic in situ hybridization(CISH) in the evaluation of HER2 status in breast carcinoma: comparison with immunohistochemistry and FISH. Int J Surg Pathol,2005,13(4): 343-351.
[16]于志强,韦伟,罗明华.乳腺癌患者CA153、C-erbB-2联合检测的临床意义及二者关系.华中医学杂志,2008,32(1)：20-22.
[17]麦国丰,罗荣城,马树东,等.HER-2表达与乳腺癌预后的相关性研究.解放军医学杂志.2003，28(10)：902-903.
[18]Valero V, Forbes J, Pegram MD, et al. Multi-center phase Ⅲrandomized trial comparing docetaxel and trastuzumab with docetaxel, carboplatin, and trastuzumab as first-line chemotherapy for patients with HER2-gene-amplified metastatic breast cancer(BCIRG 007 study):two highly active therapeutic regimens. J Clin Onc01,2011,29(2):149-156.
[19]Gusterson BA, Gelber RD, Goldhirsch A, et al. Prognostic importance of C-erbB-2 expression in breast cancer. J Clin Oncol,1997,10(7):1049-1056.
[20]Muss HB, Thor AD, Berry DA, et al. C-erbB-2 expression and response to adjuvant therapy in women with node-positive early breast cancer. N Engl J Med, 1994,330(18):1260-1266.
[21]Yu D, Liu B, Sun D, et al. Overexpression of both p185 c-erbB-2 expression p170 mdr-1 renders breast cancer cells highly resistance to Taxol. Oncogene, 1998,16(16):2087-2094.
[1]Jemal A, Siegel R, Ward E, et al. Cancer statistics,2009. CA Cancer J Clin 2009:59:225-249.
[2]连婧,李丽,孙瑞芳,等.乳腺癌组织中Ki67、C-erbB-2、VEGF表达的相关性及临床意义.山西医科大学学报,2009,40(2)：125-127.
[3]鲍炜,裘秀香.HER2分子与肿瘤靶向治疗.医学分子生物学杂志,2006,3(2)：129-132.
[4]Galiegus S, Casellas P, Kramar A, et al. Immunohistochemical assessment of the peripheral benzodiazepine receptor in breast cancer and its relationship with survival. Clin Cancer Res,2004,10(6):2058-2064.
[5]Kleer CG, Van Golen KL, Braun T, et al. Persistent E-cadherin expression in inflammatory breast cancer. Mod Pathol,2001,14(5):458-464.
[6]Rohan TE, Li SQ, Hartwick R, et al. p53 alterations and protein accmulation in benign breast tissue and breast cancer risk:a cohort study. Cancer Epidemal Biomarkers Prey,2006,15(7):1316-1323.
[7]Li-Ning-T E, Ronchetti R, Torres-Cabala C, el al. Role of chromogenic in situ hybridization(CISH) in the evaluation of HER2 status in breast carcinoma: comparison with immunohistochemistry and FISH. Int J Surg Pathol,2005,13(4): 343-351.
[8]Press MF, Slamon DJ, Flom KJ, et al. Evaluation of HER-2/neu gene amplification and over-expression:comparison of frequently used assay methods in a molecularly characterized cohort of breast cancer specimens. J Clin Oncol,2002, 20(14):3095-3105.
[9]Ross JS, Gray GS. Targeted therapy for cancer:the HER-2/neu and Herceptin story. Cl in Leadersh Manag Rev,2003,17(6):333-340.
[10]于志强,韦伟,罗明华.乳腺癌患者CA153、C-erbB-2联合检测的临床意义及二者关系.华中医学杂志,2008,32(1)：20-22.
[11]王洪,祁保圈.乳腺癌C-erbB-2的表达与淋巴结转移的关系及其临床意义.地方病通报,2008,23(1)：89-91.
[12]胡江辉,赵文健,谢开红等.乳腺癌激素受体、c-erbB-2、P53、nm23基因的表达及与临床病理特征的关系.实用医技杂志,2007,14(22)：2532.
[13]王四玲C-erbB-2在乳腺癌中的表达及与淋巴结转移的关系.河南肿瘤学杂志,2003,16(1)：14-15.
[14]杨玲芳,费绍华,殷梅英等.乳腺癌p16、nm23、C-erbB-2、PS2表达与腋下淋巴结转移的相关分析.青海医药杂志,2002,32(8)：1-3.
[15]Nabholtz JM, Slamon D. New adjuvant strategies for breast cancer:meeting the challenge of integrating chemotherapy and trastuzumab(Hereceptin). Semin Oncol, 2001,28(1 Suppl 3):1-12.
[16]Valero V, Forbes J, Pegram MD, et al. Multi-center phase Ⅲ randomized trial comparing docetaxel and trastuzumab with docetaxel, carboplatin, and trastuzumab as first-line chemotherapy for patients with HER2-gene-amplif ied metastatic breast cancer(BCIRG 007 study):two highly active therapeutic regimens. J Clin Onc01,2011,29(2):149-156.
[17]Geyer CE, Forster J, Lindquist D, et al. Lapatinib plus capecitabine for HER2-positive advanced breast cancer. N Engl J Med,2006,355(26):2733-43.
[18]麦国丰,罗荣城,马树东,等.HER-2表达与乳腺癌预后的相关性研究.解放军医学杂志.2003，28(10)：902-903.
[19]Gusterson BA, Gelber RD, Goldhirsch A, et al. Prognostic importance of C-erbB-2 expression in breast cancer. J Clin Oncol,1997,10(7):1049-1056.
[20]Muss HB, Thor AD, Berry DA, et al. C-erbB-2 expression and response to adjuvant therapy in women with node-positive early breast cancer. N Engl J Med, 1994,330 (18):1260-1266.
[21]Yu D, Liu B, Sun D, et al. Overexpression of both p185 c-erbB-2 expression p170 mdr-1 renders breast cancer cells highly resistance to Taxol. Oncogene, 1998,16(16):2087-2094.
[22]]丁渭,郑春艳,贺智敏,等.HER-2介导乳腺癌细胞多药耐药的作用和机制.国际病理科学与临床杂志.2005,25(5)：381-385.
[23]Herynk MH, Parra I, Cui Y, et al. Association between the estrogen receptor αA908G mutation and outcomes in invasive breast cancer. Clin Cancer Res,2007,13(11): 3235-3243.
[24]Suqiura H, Toyama T, Hara Y, et al. Expression of estrogen receptor beta wild-type and its variant ER βcx/β2 is correlated with better prognosis in breast cancer. Jpn J Clin Oncol,2007.37(11):820-828.
[25]Perou CM, Sorlie T, Eisen MB, et al. Molecular portraits of human breast tumors. Nature,2000,406(6797):747-752.
[26]Rouzier R, Perou CM, Symmans WF, et al. Breast cancer molecular subtypes respond differently to preoperative chemotherapy. Clin Cancer Res,2005,11(16):5678-5685.
[27]Conforti R, Boulet T, Tomasic G, et al. Breast cancer molecular sub-classification and estrogen receptor expression to predict efficacy of adjuvant anthracyclines-based chemotherapy:a biomarker study from two randomized trials. Ann Oncol,2007,18(9):1477-1483.
[28]赵晶,付丽.乳腺癌的分子分型.中华乳腺病杂志,2009,3(2)：195-203.
[29]Carey LA, Dees EC, Sawyer L, et al. The triple negative paradox:primary tumor chemo-sensitivity of breast cancer subtypes. Clin Cancer Res,2007, 13(8):2329-2334.
[30]Rakha EA, EI Rehim DA, Paish C, et al. Basal phenotype identifies a poor prognostic subgroup of breast cancer of clinical importance. Eur J Cancer,2006,42:3149-3156.
[31]徐媛媛.生长因子及其受体作为乳腺癌转移与预后血清标志物的临床价值.中国肿瘤临床,2010,37(4):234-237
[32]Konukoglu D, Turhan MS, Celik V, et al. Relation of serum vascular endothelial growth factor as an angiogenesis biomarker with nitric oxide & urokinase-type plasminogen activator in breast cancer patients. Indian J Med Res, 2007,125(6):747-751.
[33]Byrne GJ, McDowell G, Agarawal R, et al. Serum vascular endothelial growth factor in breast cancer. Anticancer Res,2007,27(5B):3481-3487.
[34]Mohle R, Green D, Moore MA, et al. Constitutive production and thrombin-induced release of vascular endothelial growth factor by human megakaryocytes and platelets. Proc Natl Acad Sci USA,1997,94(2):663-668.
[35]张江宇,王颀,张雅洁.CD105与肿瘤关系及进展.中华肿瘤防治杂志,2007,4(18)：1433-1436.
[36]Pang D, Liu F, Xue YW, et al. Clinicopathologic significance of CD105 mRNA expression in human breast carcinoma. Zhonghua Zhong Liu Za Zhi,2005,27(1):38-40.
[37]陆光明,李字清,梅开勇.C-erbB-2、p53、Ki67、ER、PR在乳腺癌中的表达及其临床意义.围际医药卫生导报,2008,14(23)：12.
[38]强欣.乳腺癌组织中C-erbB-2、p53、ER、PR的表达与预后因素的关系.内蒙古民族大学学报,2008,23(4)：423.
[39]Rohan TE, Li SQ, Hartwick R, et al. p53 alterations and protein accmulation in benign breast tissue and breast cancer risk:a cohort study. Cancer Epidemal Biomarkers Prev,2006,15(71):1316-1323.
[40]王玉,王晋芬ER PR Ki67 P53在乳腺癌中表达的相关分析及临床意义.山西医药杂志,2008,37(4)：320-321.
[41]金茂和,马煜,严娟英.乳腺癌PCNA, p53及HER-2的表达与淋巴结转移相关性的临床研究.陕西肿瘤医学,2002,10(2)：96.
[42]Tiezzi DG, Andrade JM, Ribeiro-Silva A, et al. HER-2, p53, p21 and hormonal receptors proteins expression as predictive factors of response and in locally advanced breast cancer treated with neoadjuvant docetaxel plus epirubicin combination. BMC Cancer,2007,26(7):36.
[43]胡黉宏,宋和平,林晓燕等.Ki67、P53抗原和nm23蛋白在乳腺癌中的表达及其临床意义.中国医药指南,2008.6(3)：15-18.
[44]朱学强,任刚,胡洪林.乳腺癌组织中VEGF、C-erbB2、P53及Ki67的表达及临床意义.西部医学,2009,21(3)：428-431.
[45]刘刚,俞薇薇.EBV、ki67、ERKI在乳腺癌中的表达及其相关性.实用临床医学,2008,9(3)：129-130.
[46]Tan PH, Bay BH, Yip G, et al. Immunohistochemical detection of Ki67 in breast cancer correlates with transcriptional regulation of genes related to apoptosis and cell death. Mod Pathol,2005,18(3):374-381.
[47]李梅,陈芸,张丽娟等Survivin、p53、Ki-67在乳腺癌组织中的表达及其意义.实用癌症杂志,2007,22(2)：156.
[48]张继涛,周文学Survivin、Ki67基因在乳腺癌组织中的表达及其与C-erbB-2基因的关系.齐齐哈尔医学院学报,2008,29(4)：408-411.
[49]Joncourt F, Buser K, Altermatt H, et al. Multiple drug resistance parameter expression in ovarian cancer. Gynecol Oncol,1998,70(2):176-182.
[50]Pujol JL, Simony J, Gautier V, et al. Immunohistochemical study of P-glycoprotein distribution in lung cancer. Lung Cancer,1993,10 (1-2):1-12.
[51]Pohl G, Filipits M, Suchomel RW, et al. Expression of lung resistance protein (LRP) in primary breast cancer. Anticancer Res,1999,19(6B):5051-5055.
[52]Goto S, lida T, Cho S, et al. Overexpression of glutathione-S-transf erase Ⅱ enhances the adduct formation of cisplatin with glutathione in human cancer cells[J]. Free Radi Res,1999,31(6):549-558.
[53]Donald G, Guinee JR, Joseph A, et al. Comparison of DNA topoisomeraseⅡ a expression in Small cell and non small Cell Carcinoma of the lung. Cancer,1996,78:729-735.
[54]Ambudkar SV, Dey S, Hrycyna CA, et al. Biochemical, cellular and pharmacological aspects of the multidrug transporter. Annu Rev Pharmacol Toxicol,1999,39:361-398.
[55]Trock BJ, Leonessa F, Clarke R. Multi-drug resistance in breast cancer:a meta-analysis of MDR1/gp170 expression and its possible functional significance. J Natl Cancer Inst.1997,89(13):917-931.
[56]孙浩,于晓东P-gp、GST-π和C-erbB-2在乳腺癌中的表达及其临床意义.中国普外基础与 临床杂志,2009,16(1)：56-59.
[57]Chung HC, Rha SY, Kim JH, et al. P-glycoprotein:the intermediate end point of drug response to induction chemotherapy in locally advanced breast cancer. Breast Cancer Res Treat.1997,42(1):65-72.
[58]Townsend DM, Tew KD. The role of glutathione-S-transferase in anti-cancer drug resistance. Oncogene,2003,22(47):7369-7375.
[59]王慧群,张开光.谷胱甘肽S-转移酶-π与肿瘤多药耐药的研究进展.胃肠病学,2010,15(12)：755-757.
[60]李海峰,张晓丽,王晓寅,等.谷胱甘肽S转移酶在胃肠腺癌和乳腺癌中表达的临床意义.中国老年学杂志,2010,3(2)：260-261.
[61]Pohl G, Filipits M, Suchomel RW, et al. Expression of lung resistance protein(LRP) in primary breast cancer. Anti Cancer Res,1999,19 (6B):5051-5055.
[62]穆殿斌,仲伟霞,贺爱丽,等.乳腺癌P-gP、LRP、GST-π、 TOPO-Ⅱ的表达及其与术前化疗的关系.实用医技杂志,2004,11(8B)：1530-1532.
[2]Press MF, Slamon DJ, Flom KJ, et al. Evaluation of HER-2/neu gene amplification and overexpression:comparison of frequently used assay methods in a molecularly characterized cohort of breast cancer specimens. J Clin Oncol,2002, 20(14):3095-3105.
[3]Ross JS, Gray GS. Targeted therapy for cancer:the HER-2/neu and Herceptin story. Clin Leadersh Manag Rev,2003,17 (6):333-340.
[4]丁渭,郑春艳,贺智敏,等.HER-2介导乳腺癌细胞多药耐药的作用和机制.国际病理科学与临床杂志.2005,25(5)：381-385.
[5]Ambudkar SV, Dey S, Hrycyna CA, et al. Biochemical, cellular and pharmacological aspects of the multidrug transporter. Annu Rev Pharmacol Toxicol,1999,39:361-398.
[6]Trock BJ, Leonessa F, Clarke R. Multidrug resistance in breast cancer:a meta-analysis of MDR1/gp170 expression and its possible functional significance. J Natl Cancer Inst.1997,89(13):917-931.
[7]孙浩,于晓东P-gp、GST-π、C-erbB-2在乳腺癌中的表达及临床意义.中国普外基础与临床杂志.2009,26(1)：56-59.
[8]陈亦欣,陈伟,王秀清,等.乳腺癌组织中MDR1, TOPOⅡ和C-erbB-2的表达及其相互关系.中国现代医学杂志.2003,13(16)：31-34.
[9]Chung HC, Rha SY, Kim JH, et al. P-glycoprotein:the intermediate end point of drug response to induction chemotherapy in locally advanced breast cancer. Breast Cancer Res Treat.1997,42(1)：65-72.
[10]Bellamy CO, Harrison DJ. Evaluation of glutathione-S-transferase Pi in non-invasive ductal carcinoma of breast. Br J Cancer.1994,69(1):183-185.
[11]李杰,许良中,吴炅.三种耐药基因蛋白表达在乳腺癌中的临床意义.癌症.2001,20(8)：866-868.
[12]位嘉,刘芳芳,付丽.拓扑异构酶Ⅱα在乳腺癌中的研究现状.中华病理学杂志.2008,37(2)：132-135.
[13]连婧,李丽,孙瑞芳,等.乳腺癌组织中Ki67、C-erbB-2、VEGF表达的相关性及临床意义.山西医科大学学报,2009,40(2)：125-127.
[14]Rohan TE, Li SQ, Hartwick R, et al. p53 alterations and protein aecmulation in benign breast tissue and breast cancer risk:aeohort study. Cancer Epidemiol Biomarkers Prey,2006,15(7):1316-1323.
[15]Li-Ning-T E, Ronchetti R, Torres-Cabala C, el al. Role of chromogenic in situ hybridization(CISH) in the evaluation of HER2 status in breast carcinoma: comparison with immunohistochemistry and FISH. Int J Surg Pathol,2005,13(4): 343-351.
[16]于志强,韦伟,罗明华.乳腺癌患者CA153、C-erbB-2联合检测的临床意义及二者关系.华中医学杂志,2008,32(1)：20-22.
[17]麦国丰,罗荣城,马树东,等.HER-2表达与乳腺癌预后的相关性研究.解放军医学杂志.2003，28(10)：902-903.
[18]Valero V, Forbes J, Pegram MD, et al. Multi-center phase Ⅲrandomized trial comparing docetaxel and trastuzumab with docetaxel, carboplatin, and trastuzumab as first-line chemotherapy for patients with HER2-gene-amplified metastatic breast cancer(BCIRG 007 study):two highly active therapeutic regimens. J Clin Onc01,2011,29(2):149-156.
[19]Gusterson BA, Gelber RD, Goldhirsch A, et al. Prognostic importance of C-erbB-2 expression in breast cancer. J Clin Oncol,1997,10(7):1049-1056.
[20]Muss HB, Thor AD, Berry DA, et al. C-erbB-2 expression and response to adjuvant therapy in women with node-positive early breast cancer. N Engl J Med, 1994,330(18):1260-1266.
[21]Yu D, Liu B, Sun D, et al. Overexpression of both p185 c-erbB-2 expression p170 mdr-1 renders breast cancer cells highly resistance to Taxol. Oncogene, 1998,16(16):2087-2094.
[1]Jemal A, Siegel R, Ward E, et al. Cancer statistics,2009. CA Cancer J Clin 2009:59:225-249.
[2]连婧,李丽,孙瑞芳,等.乳腺癌组织中Ki67、C-erbB-2、VEGF表达的相关性及临床意义.山西医科大学学报,2009,40(2)：125-127.
[3]鲍炜,裘秀香.HER2分子与肿瘤靶向治疗.医学分子生物学杂志,2006,3(2)：129-132.
[4]Galiegus S, Casellas P, Kramar A, et al. Immunohistochemical assessment of the peripheral benzodiazepine receptor in breast cancer and its relationship with survival. Clin Cancer Res,2004,10(6):2058-2064.
[5]Kleer CG, Van Golen KL, Braun T, et al. Persistent E-cadherin expression in inflammatory breast cancer. Mod Pathol,2001,14(5):458-464.
[6]Rohan TE, Li SQ, Hartwick R, et al. p53 alterations and protein accmulation in benign breast tissue and breast cancer risk:a cohort study. Cancer Epidemal Biomarkers Prey,2006,15(7):1316-1323.
[7]Li-Ning-T E, Ronchetti R, Torres-Cabala C, el al. Role of chromogenic in situ hybridization(CISH) in the evaluation of HER2 status in breast carcinoma: comparison with immunohistochemistry and FISH. Int J Surg Pathol,2005,13(4): 343-351.
[8]Press MF, Slamon DJ, Flom KJ, et al. Evaluation of HER-2/neu gene amplification and over-expression:comparison of frequently used assay methods in a molecularly characterized cohort of breast cancer specimens. J Clin Oncol,2002, 20(14):3095-3105.
[9]Ross JS, Gray GS. Targeted therapy for cancer:the HER-2/neu and Herceptin story. Cl in Leadersh Manag Rev,2003,17(6):333-340.
[10]于志强,韦伟,罗明华.乳腺癌患者CA153、C-erbB-2联合检测的临床意义及二者关系.华中医学杂志,2008,32(1)：20-22.
[11]王洪,祁保圈.乳腺癌C-erbB-2的表达与淋巴结转移的关系及其临床意义.地方病通报,2008,23(1)：89-91.
[12]胡江辉,赵文健,谢开红等.乳腺癌激素受体、c-erbB-2、P53、nm23基因的表达及与临床病理特征的关系.实用医技杂志,2007,14(22)：2532.
[13]王四玲C-erbB-2在乳腺癌中的表达及与淋巴结转移的关系.河南肿瘤学杂志,2003,16(1)：14-15.
[14]杨玲芳,费绍华,殷梅英等.乳腺癌p16、nm23、C-erbB-2、PS2表达与腋下淋巴结转移的相关分析.青海医药杂志,2002,32(8)：1-3.
[15]Nabholtz JM, Slamon D. New adjuvant strategies for breast cancer:meeting the challenge of integrating chemotherapy and trastuzumab(Hereceptin). Semin Oncol, 2001,28(1 Suppl 3):1-12.
[16]Valero V, Forbes J, Pegram MD, et al. Multi-center phase Ⅲ randomized trial comparing docetaxel and trastuzumab with docetaxel, carboplatin, and trastuzumab as first-line chemotherapy for patients with HER2-gene-amplif ied metastatic breast cancer(BCIRG 007 study):two highly active therapeutic regimens. J Clin Onc01,2011,29(2):149-156.
[17]Geyer CE, Forster J, Lindquist D, et al. Lapatinib plus capecitabine for HER2-positive advanced breast cancer. N Engl J Med,2006,355(26):2733-43.
[18]麦国丰,罗荣城,马树东,等.HER-2表达与乳腺癌预后的相关性研究.解放军医学杂志.2003，28(10)：902-903.
[19]Gusterson BA, Gelber RD, Goldhirsch A, et al. Prognostic importance of C-erbB-2 expression in breast cancer. J Clin Oncol,1997,10(7):1049-1056.
[20]Muss HB, Thor AD, Berry DA, et al. C-erbB-2 expression and response to adjuvant therapy in women with node-positive early breast cancer. N Engl J Med, 1994,330 (18):1260-1266.
[21]Yu D, Liu B, Sun D, et al. Overexpression of both p185 c-erbB-2 expression p170 mdr-1 renders breast cancer cells highly resistance to Taxol. Oncogene, 1998,16(16):2087-2094.
[22]]丁渭,郑春艳,贺智敏,等.HER-2介导乳腺癌细胞多药耐药的作用和机制.国际病理科学与临床杂志.2005,25(5)：381-385.
[23]Herynk MH, Parra I, Cui Y, et al. Association between the estrogen receptor αA908G mutation and outcomes in invasive breast cancer. Clin Cancer Res,2007,13(11): 3235-3243.
[24]Suqiura H, Toyama T, Hara Y, et al. Expression of estrogen receptor beta wild-type and its variant ER βcx/β2 is correlated with better prognosis in breast cancer. Jpn J Clin Oncol,2007.37(11):820-828.
[25]Perou CM, Sorlie T, Eisen MB, et al. Molecular portraits of human breast tumors. Nature,2000,406(6797):747-752.
[26]Rouzier R, Perou CM, Symmans WF, et al. Breast cancer molecular subtypes respond differently to preoperative chemotherapy. Clin Cancer Res,2005,11(16):5678-5685.
[27]Conforti R, Boulet T, Tomasic G, et al. Breast cancer molecular sub-classification and estrogen receptor expression to predict efficacy of adjuvant anthracyclines-based chemotherapy:a biomarker study from two randomized trials. Ann Oncol,2007,18(9):1477-1483.
[28]赵晶,付丽.乳腺癌的分子分型.中华乳腺病杂志,2009,3(2)：195-203.
[29]Carey LA, Dees EC, Sawyer L, et al. The triple negative paradox:primary tumor chemo-sensitivity of breast cancer subtypes. Clin Cancer Res,2007, 13(8):2329-2334.
[30]Rakha EA, EI Rehim DA, Paish C, et al. Basal phenotype identifies a poor prognostic subgroup of breast cancer of clinical importance. Eur J Cancer,2006,42:3149-3156.
[31]徐媛媛.生长因子及其受体作为乳腺癌转移与预后血清标志物的临床价值.中国肿瘤临床,2010,37(4):234-237
[32]Konukoglu D, Turhan MS, Celik V, et al. Relation of serum vascular endothelial growth factor as an angiogenesis biomarker with nitric oxide & urokinase-type plasminogen activator in breast cancer patients. Indian J Med Res, 2007,125(6):747-751.
[33]Byrne GJ, McDowell G, Agarawal R, et al. Serum vascular endothelial growth factor in breast cancer. Anticancer Res,2007,27(5B):3481-3487.
[34]Mohle R, Green D, Moore MA, et al. Constitutive production and thrombin-induced release of vascular endothelial growth factor by human megakaryocytes and platelets. Proc Natl Acad Sci USA,1997,94(2):663-668.
[35]张江宇,王颀,张雅洁.CD105与肿瘤关系及进展.中华肿瘤防治杂志,2007,4(18)：1433-1436.
[36]Pang D, Liu F, Xue YW, et al. Clinicopathologic significance of CD105 mRNA expression in human breast carcinoma. Zhonghua Zhong Liu Za Zhi,2005,27(1):38-40.
[37]陆光明,李字清,梅开勇.C-erbB-2、p53、Ki67、ER、PR在乳腺癌中的表达及其临床意义.围际医药卫生导报,2008,14(23)：12.
[38]强欣.乳腺癌组织中C-erbB-2、p53、ER、PR的表达与预后因素的关系.内蒙古民族大学学报,2008,23(4)：423.
[39]Rohan TE, Li SQ, Hartwick R, et al. p53 alterations and protein accmulation in benign breast tissue and breast cancer risk:a cohort study. Cancer Epidemal Biomarkers Prev,2006,15(71):1316-1323.
[40]王玉,王晋芬ER PR Ki67 P53在乳腺癌中表达的相关分析及临床意义.山西医药杂志,2008,37(4)：320-321.
[41]金茂和,马煜,严娟英.乳腺癌PCNA, p53及HER-2的表达与淋巴结转移相关性的临床研究.陕西肿瘤医学,2002,10(2)：96.
[42]Tiezzi DG, Andrade JM, Ribeiro-Silva A, et al. HER-2, p53, p21 and hormonal receptors proteins expression as predictive factors of response and in locally advanced breast cancer treated with neoadjuvant docetaxel plus epirubicin combination. BMC Cancer,2007,26(7):36.
[43]胡黉宏,宋和平,林晓燕等.Ki67、P53抗原和nm23蛋白在乳腺癌中的表达及其临床意义.中国医药指南,2008.6(3)：15-18.
[44]朱学强,任刚,胡洪林.乳腺癌组织中VEGF、C-erbB2、P53及Ki67的表达及临床意义.西部医学,2009,21(3)：428-431.
[45]刘刚,俞薇薇.EBV、ki67、ERKI在乳腺癌中的表达及其相关性.实用临床医学,2008,9(3)：129-130.
[46]Tan PH, Bay BH, Yip G, et al. Immunohistochemical detection of Ki67 in breast cancer correlates with transcriptional regulation of genes related to apoptosis and cell death. Mod Pathol,2005,18(3):374-381.
[47]李梅,陈芸,张丽娟等Survivin、p53、Ki-67在乳腺癌组织中的表达及其意义.实用癌症杂志,2007,22(2)：156.
[48]张继涛,周文学Survivin、Ki67基因在乳腺癌组织中的表达及其与C-erbB-2基因的关系.齐齐哈尔医学院学报,2008,29(4)：408-411.
[49]Joncourt F, Buser K, Altermatt H, et al. Multiple drug resistance parameter expression in ovarian cancer. Gynecol Oncol,1998,70(2):176-182.
[50]Pujol JL, Simony J, Gautier V, et al. Immunohistochemical study of P-glycoprotein distribution in lung cancer. Lung Cancer,1993,10 (1-2):1-12.
[51]Pohl G, Filipits M, Suchomel RW, et al. Expression of lung resistance protein (LRP) in primary breast cancer. Anticancer Res,1999,19(6B):5051-5055.
[52]Goto S, lida T, Cho S, et al. Overexpression of glutathione-S-transf erase Ⅱ enhances the adduct formation of cisplatin with glutathione in human cancer cells[J]. Free Radi Res,1999,31(6):549-558.
[53]Donald G, Guinee JR, Joseph A, et al. Comparison of DNA topoisomeraseⅡ a expression in Small cell and non small Cell Carcinoma of the lung. Cancer,1996,78:729-735.
[54]Ambudkar SV, Dey S, Hrycyna CA, et al. Biochemical, cellular and pharmacological aspects of the multidrug transporter. Annu Rev Pharmacol Toxicol,1999,39:361-398.
[55]Trock BJ, Leonessa F, Clarke R. Multi-drug resistance in breast cancer:a meta-analysis of MDR1/gp170 expression and its possible functional significance. J Natl Cancer Inst.1997,89(13):917-931.
[56]孙浩,于晓东P-gp、GST-π和C-erbB-2在乳腺癌中的表达及其临床意义.中国普外基础与 临床杂志,2009,16(1)：56-59.
[57]Chung HC, Rha SY, Kim JH, et al. P-glycoprotein:the intermediate end point of drug response to induction chemotherapy in locally advanced breast cancer. Breast Cancer Res Treat.1997,42(1):65-72.
[58]Townsend DM, Tew KD. The role of glutathione-S-transferase in anti-cancer drug resistance. Oncogene,2003,22(47):7369-7375.
[59]王慧群,张开光.谷胱甘肽S-转移酶-π与肿瘤多药耐药的研究进展.胃肠病学,2010,15(12)：755-757.
[60]李海峰,张晓丽,王晓寅,等.谷胱甘肽S转移酶在胃肠腺癌和乳腺癌中表达的临床意义.中国老年学杂志,2010,3(2)：260-261.
[61]Pohl G, Filipits M, Suchomel RW, et al. Expression of lung resistance protein(LRP) in primary breast cancer. Anti Cancer Res,1999,19 (6B):5051-5055.
[62]穆殿斌,仲伟霞,贺爱丽,等.乳腺癌P-gP、LRP、GST-π、 TOPO-Ⅱ的表达及其与术前化疗的关系.实用医技杂志,2004,11(8B)：1530-1532.